<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668849</url>
  </required_header>
  <id_info>
    <org_study_id>12.0220</org_study_id>
    <nct_id>NCT01668849</nct_id>
  </id_info>
  <brief_title>Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer</brief_title>
  <official_title>Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>James Graham Brown Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the ability of grape exosomes, given to the subject as grape powder,&#xD;
      as an important anti-inflammatory agent to reduce the incidence of oral mucositis during&#xD;
      radiation and chemotherapy treatment for head and neck tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate the ability of plant (grape) exosomes to prevent&#xD;
      oral mucositis associated with chemoradiation treatment of head and neck cancer. Also, to be&#xD;
      evaluated is the effect of grape exosomes on the production of cytokines and immune responses&#xD;
      to tumor exosomal antigens, metabolic and molecular markers in these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2, 2012</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain caused by oral mucositis</measure>
    <time_frame>Total followup of six months</time_frame>
    <description>Extent of pain from oral mucositis will be evaluated weekly during treatment (6 to 7 weeks) and for six months following the completion of treatment which will last approximately 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of immune biomarkers in blood</measure>
    <time_frame>Within three days of the completion of radiation therapy which will last approximately 30 days.</time_frame>
    <description>Levels of immune biomarkers (cytokines, T cells NK Cells CD11cIL12)in the blood at the time of completion of radiation therapy will be compared to baseline levels.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of immune biomarkers in mucosal tissue</measure>
    <time_frame>Within three days of the completion of radiation therapy which will last approximately thirty days.</time_frame>
    <description>Levels of immune biomarkers (CD3, CD8, CD11b, F4/80, BRDU)in scrapings of mucosal tissue at the time of completion of radiation therapy will be compared to baseline levels.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Oral Mucositis</condition>
  <arm_group>
    <arm_group_label>1 - Grape extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grape extract self-administered daily by mouth for 35 days during chemoradiation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Lortab, Fentanyl patch, mouthwash</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard oral mucositis therapy such as pain medication and anti-fungal mouth washes will be prescribed according to product labels.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grape extract</intervention_name>
    <description>Grape extract self-administered by mouth daily for 35 days</description>
    <arm_group_label>1 - Grape extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lortab, Fentanyl patch, mouthwash</intervention_name>
    <description>Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash</description>
    <arm_group_label>2 - Lortab, Fentanyl patch, mouthwash</arm_group_label>
    <other_name>Lortab 5-10 mg</other_name>
    <other_name>Fentanyl patch 25 mcgs</other_name>
    <other_name>Mary's Magic Mouthwash</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have definitive diagnosis of head and neck cancer.&#xD;
&#xD;
          -  Concurrent chemoradiation treatment of the primary tumor must be an option for the&#xD;
             newly diagnosed cancer.&#xD;
&#xD;
          -  Patients must be informed of the investigational nature of this study and sign and&#xD;
             give written informed consent in accordance with institutional and federal guidelines.&#xD;
&#xD;
          -  Absence of life limiting medical conditions&#xD;
&#xD;
          -  Ability to understand and willingness to sign a written informed consent document.&#xD;
&#xD;
          -  ECOG performance status 0, 1, or 2 (Karnofsky &gt; 60%).&#xD;
&#xD;
          -  Patients must have adequate bone marrow function. ANC &gt; 1000/microL and Platelet count&#xD;
             &gt;100,000/microL&#xD;
&#xD;
          -  Age &gt;20 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known familial head and neck cancer syndrome&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known HIV&#xD;
&#xD;
          -  Patients receiving immunosuppressive drugs&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Active second malignancy in the last 5 years&#xD;
&#xD;
          -  Patients receiving any other investigational agent(s)&#xD;
&#xD;
          -  Patients who have received any prior chemotherapy or radiation therapy to the primary&#xD;
             head and neck cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Redman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>James Graham Brown Cancer Center, University of Louisville</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.browncancercenter.org</url>
    <description>James Graham Brown Cancer Center, Louisville, Kentucky</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>August 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Rebecca Redman</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Plant exosomes</keyword>
  <keyword>Grape exosomes</keyword>
  <keyword>Grape extract</keyword>
  <keyword>Oral mucositis</keyword>
  <keyword>Head and Neck Cancer</keyword>
  <keyword>Immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen, hydrocodone drug combination</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

